Program
Goserelin
Also written as “Goserelin acetate”, “ZOLADEX” and “Inj. Goserelin (Test) Subcutaneously”.
Its studies are mostly in Breast Neoplasms · Prostatic Neoplasms · Metrorrhagia, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 80 open or running | phase 4since Oct 26, 2005 | Oct 10, 2005 | none ahead |
| Eurofarma Laboratorios | 20 open or running | phase 3since Apr 29, 2019 | Apr 29, 2019 | none ahead |
| Peptigroupe | 10 open or running | phase 1since Jun 9, 2020 | Jun 9, 2020 | none ahead |
| TerSera Therapeutics | 11 open or running | phase 1since Dec 16, 2025 | Dec 16, 2025 | Mar 30, 2027phase 1 · NCT07310420 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 10, 2005First study: phase 2 study in Breast NeoplasmsNew to AstraZenecaAstraZeneca · NCT00235937 · 45 enrolled · France
- Oct 26, 2005Phase 4 study in Prostatic NeoplasmsAstraZeneca · NCT00255268 · 15 enrolled · Mexico
- Mar 16, 2006Phase 2 study in Breast NeoplasmsAstraZeneca · NCT00303524 · 170 enrolled · Japan
- May 3, 2006Phase 2 study in NeoplasmsAstraZeneca · NCT00322348 · 98 enrolled · Czech Republic, Russian Federation, Ukraine
- Apr 23, 2009Phase 3 study in Breast NeoplasmsAstraZeneca · NCT00888082 · 102 enrolled · Turkey
- Feb 22, 2010Phase 3 study in Breast NeoplasmsAstraZeneca · NCT01073865 · 222 enrolled · India, Japan, Korea, Republic of and more
- Jun 27, 2018Phase 3 study in Breast NeoplasmsAstraZeneca · NCT03658213 · China
- Mar 21, 2019Phase 4 study in Advanced Prostate CancerAstraZeneca · NCT03971110 · 9 enrolled · China
- Apr 29, 2019Eurofarma Laboratorios's first studies: 2 phase 3 studiesNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT03936933, NCT03936218
- Jun 9, 2020Peptigroupe's first study: phase 1 study in MetrorrhagiaNew to PeptigroupePeptigroupe · NCT04428684 · 80 enrolled · Ukraine
- Dec 16, 2025TerSera Therapeutics's first study: phase 1 study in Breast NeoplasmsNew to TerSera TherapeuticsTerSera Therapeutics · NCT07310420 · 176 planned · United States
Ahead
- Mar 30, 2027Primary completion: phase 1 study in Breast NeoplasmsTerSera Therapeutics · NCT07310420
TargetBeta
“A synthetic decapeptide analog of luteinizing hormone-releasing hormone (LHRH) with antineoplastic activity”NCIt, by rule
“Gonadotropin-releasing hormone receptor agonist”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| triptorelinrule | Ipsen | phase 4 | 21 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07310420Breast Neoplasms · United States | 1 | Recruiting | TerSera Therapeutics | Mar 30, 2027 | 176 |
| NCT04428684Metrorrhagia · Ukraine | 1 | Completed | Peptigroupe | Apr 1, 2020 | 80 |
| NCT03936933Breast Neoplasms · India | 3 | Terminated | Eurofarma Laboratorios | Sep 30, 2024 | 6 |
| NCT03936218Advanced Prostate Cancer · India | 3 | Completed | Eurofarma Laboratorios | Nov 30, 2023 | 94 |
| NCT03971110Advanced Prostate Cancer · China | 4 | Terminated | AstraZeneca | Nov 9, 2022 | 9 |
| NCT03658213Breast Neoplasms · China | 3 | Withdrawn | AstraZeneca | Nov 4, 2021 | 0 |
| NCT01073865Breast Neoplasms · India, Japan, Korea, Republic of and more | 3 | Completed | AstraZeneca | Sep 19, 2012 | 222 |
| NCT00888082Breast Neoplasms · Turkey | 3 | Withdrawn | AstraZeneca | Apr 2012 | 102 |
| NCT00322348Neoplasms · Czech Republic, Russian Federation, Ukraine | 2 | Completed | AstraZeneca | 98 | |
| NCT00303524Breast Neoplasms · Japan | 2 | Completed | AstraZeneca | Aug 2007 | 170 |
| NCT00255268Prostatic Neoplasms · Mexico | 4 | Withdrawn | AstraZeneca | 15 | |
| NCT00235937Breast Neoplasms · France | 2 | Completed | AstraZeneca | 45 |
How it is read
Names in the registry
- “Goserelin acetate”, 5 entries
- “Goserelin”, 2 entries
- “ZOLADEX”, 1 entry
- “Inj. Goserelin (Test) Subcutaneously”, 1 entry
- “Goserelin acetate 3.6 mg Injection”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 10 studies
- Prostatic Neoplasms, 3 studies
- Metrorrhagia, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.